CA2637698C - Medicament for treatment of a tumor comprising a endostatin and polyethylene glycol conjugate - Google Patents

Medicament for treatment of a tumor comprising a endostatin and polyethylene glycol conjugate Download PDF

Info

Publication number
CA2637698C
CA2637698C CA2637698A CA2637698A CA2637698C CA 2637698 C CA2637698 C CA 2637698C CA 2637698 A CA2637698 A CA 2637698A CA 2637698 A CA2637698 A CA 2637698A CA 2637698 C CA2637698 C CA 2637698C
Authority
CA
Canada
Prior art keywords
endostatin
conjugate
polyethylene glycol
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2637698A
Other languages
English (en)
French (fr)
Other versions
CA2637698A1 (en
Inventor
Yongzhang Luo
Qing Han
Qingxin Lei
Guodong Chang
Yan Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of CA2637698A1 publication Critical patent/CA2637698A1/en
Application granted granted Critical
Publication of CA2637698C publication Critical patent/CA2637698C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2637698A 2006-01-20 2007-01-19 Medicament for treatment of a tumor comprising a endostatin and polyethylene glycol conjugate Active CA2637698C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200610011247.9 2006-01-20
CNB2006100112479A CN100475270C (zh) 2006-01-20 2006-01-20 一种治疗肿瘤的药物及其应用
PCT/CN2007/000204 WO2007082483A1 (en) 2006-01-20 2007-01-19 Medicament for treatment of tumor and the use thereof

Publications (2)

Publication Number Publication Date
CA2637698A1 CA2637698A1 (en) 2007-07-26
CA2637698C true CA2637698C (en) 2016-09-20

Family

ID=38287273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2637698A Active CA2637698C (en) 2006-01-20 2007-01-19 Medicament for treatment of a tumor comprising a endostatin and polyethylene glycol conjugate

Country Status (8)

Country Link
US (2) US20100285103A1 (https=)
EP (1) EP1985302B1 (https=)
JP (2) JP5687823B2 (https=)
CN (3) CN100475270C (https=)
AU (1) AU2007207268B2 (https=)
CA (1) CA2637698C (https=)
NO (1) NO20083287L (https=)
WO (1) WO2007082483A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961831B (zh) 2007-09-05 2020-06-23 江苏先声药业有限公司 一种修饰的重组人内皮抑素及其应用
CN101396347B (zh) * 2007-09-27 2011-12-14 江苏先声药物研究有限公司 一种重组人血管内皮抑制素缓释微球的制备方法
CN101265298B (zh) * 2008-04-30 2011-11-09 中国药科大学 含有非天然氨基酸的内皮抑素突变体及其衍生物
CN101642559B (zh) * 2008-06-30 2012-08-01 江苏先声药物研究有限公司 含微粉化人血管内皮抑制素的药物组合物
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
ES2891564T3 (es) * 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
CN101890155B (zh) * 2010-05-25 2012-07-25 江苏先声药物研究有限公司 一种药物组合物及其应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
JP6336389B2 (ja) * 2011-09-09 2018-06-06 チンファ ユニヴァーシティＴｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ Ａｔｐ結合部位に変異を有するエンドスタチン変異体
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
CN104031261B (zh) * 2014-06-20 2017-10-27 电子科技大学 温敏性共聚物及其水凝胶体系
CN104174015A (zh) * 2014-08-22 2014-12-03 广州安辰医药科技有限公司 疫苗组合物及其在肿瘤治疗中的用途
CN104515768B (zh) * 2014-08-29 2017-01-25 湖南新大陆生物技术有限公司 一种肿瘤特异性生长因子检测试剂盒
CN104771603B (zh) * 2015-04-17 2018-05-18 张坤镛 一种改善唾液酸异常的中药口服药及制备方法
CN106924754B (zh) * 2015-12-30 2021-11-09 北京大学 聚氨基酸偶联物
CN105646701B (zh) * 2016-03-29 2019-03-05 徐根兴 不同氨基酸结构的重组人内皮抑素蛋白及其制备方法和应用
CN107865824B (zh) * 2016-09-28 2020-04-03 山东先声生物制药有限公司 一种稳定的重组人血管内皮抑制素皮下注射组合物
EP3539570B1 (en) * 2016-11-10 2022-04-13 Beijing Protgen Ltd. Pegylated endostatin analogue and application thereof
CA3103035A1 (en) * 2017-07-30 2019-02-07 Tsinghua University Medication for inhibiting dna-pkcs
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN110870869A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含糖类营养素和常规无效化合物的药物组合物及其应用
WO2022161381A1 (zh) * 2021-01-26 2022-08-04 清华大学 血管内皮抑制素在治疗和预防冠状病毒相关疾病中的应用
CN113350576A (zh) * 2021-05-21 2021-09-07 上海大学 快慢交联互补的双网络自愈合可注射水凝胶及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911929A (en) 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
AU5858690A (en) * 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ZA991029B (en) 1998-02-09 1999-09-30 Rhone Poulenc Rorer Pharma Composition and methods for treatment of hiv infections.
US6689762B1 (en) 1998-02-09 2004-02-10 Enzon Pharmaceuticals, Inc. Composition and methods for treatment of HIV infection
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
JP4216480B2 (ja) 1999-05-17 2009-01-28 コンジュケム バイオテクノロジーズ インコーポレイテッド ウイルス感染の長期持続性融合ペプチドインヒビター
WO2001017568A2 (en) 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2002044360A2 (en) * 2000-11-28 2002-06-06 Phoenix Pharmacologics, Inc. Modified arginine deiminase
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
AU2003244515A1 (en) * 2002-02-07 2003-09-02 Novozymes Delta Limited Albumin-fused anti-angiogenesis peptides
IL166037A0 (en) * 2002-07-24 2006-01-15 Hoffmann La Roche Pegylated t1249 polypeptide
NZ538958A (en) * 2002-08-28 2006-09-29 Novartis Ag Treating disorders of the retina by increasing the in vivo concentration of endostatin in ocular tissues
US7078485B2 (en) * 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
JP2006519235A (ja) 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
EP1668129B1 (en) * 2003-08-29 2008-10-29 Children's Medical Center Corporation Anti-angiogenic peptides from the n-terminus of endostatin
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
CN100355784C (zh) 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
JP2005245269A (ja) 2004-03-03 2005-09-15 Nipro Corp 血清アルブミン多量体を含む遺伝子組換え型蛋白質
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
CN1311867C (zh) 2004-09-27 2007-04-25 侯新朴 一种用于鼻腔给药的神经生长因子制剂
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用

Also Published As

Publication number Publication date
CN104043107B (zh) 2016-09-07
EP1985302A4 (en) 2013-01-02
JP2009523743A (ja) 2009-06-25
US20180360922A1 (en) 2018-12-20
JP5687823B2 (ja) 2015-03-25
CN104043107A (zh) 2014-09-17
US20100285103A1 (en) 2010-11-11
EP1985302A1 (en) 2008-10-29
AU2007207268A1 (en) 2007-07-26
EP1985302B1 (en) 2018-01-03
NO20083287L (no) 2008-10-20
WO2007082483A1 (en) 2007-07-26
CN101405019B (zh) 2014-06-04
CN101405019A (zh) 2009-04-08
WO2007082483B1 (en) 2007-09-07
AU2007207268B2 (en) 2011-08-18
CA2637698A1 (en) 2007-07-26
CN101002946A (zh) 2007-07-25
CN100475270C (zh) 2009-04-08
JP2013163674A (ja) 2013-08-22

Similar Documents

Publication Publication Date Title
CA2637698C (en) Medicament for treatment of a tumor comprising a endostatin and polyethylene glycol conjugate
CA2637687C (en) Arginine deiminase conjugate for the treatment of tumors
CA2675231C (en) A conjugate comprising angiostatin or its fragment, the method for producing the conjugate and use thereof
JP7140454B2 (ja) ペグ化エンドスタチン類似体およびその適用
CN101596320B (zh) 一种治疗肿瘤的药物及其应用
HK1122498A (en) Medicament for treatment of tumor and the use thereof
CN103083681A (zh) 一种治疗肿瘤的药物及其应用
HK1122498B (en) Medicament for treatment of tumor and the use thereof
AU2012203658B2 (en) Complexes comprising angiostatin and its fragments, preparation preparing methods and uses thereof
HK1122739A (en) Novel compound for treatment of tumor

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240719